Magic Johnson-Backed Startup Raises $31 Million to Help Build, Expand In-House Pharmacies at 340B HIV Clinics

Alchemy announced that it has raised $31 million, as part of a campaign with NBA legend Earvin “Magic” Johnson, to help build in-house pharmacies for HIV clinics. (Credit: Shutterstock)
A California-based healthcare startup recently announced that it has raised more than $30 million, as part of a campaign with [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Lobbying Activity Did Not Slow Down in Q3, Federal Filings Suggest

340B Working Table
More than 360 firms reported lobbying on the 340B program between July 1 and Sept. 30.
The 340B drug discount program continued to be a hot topic for lobbyists in the third quarter of 2024, keeping [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

News Alert

Total 340B Drug Purchases Reached $66 Billion in 2023

Total 340B purchases reached $66.3 billion in 2023, according to new HRSA data released Oct. 18.
Drug purchases under the 340B program reached $66.3 billion in 2023, marking a 24% increase over the $54 billion in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

LA Times Says ‘No’ to California Ballot Measure That Would Affect 340B 

The Los Angeles Times’ editorial board endorsed the “no” position on Proposition 34, a 340B-realated measure which will appear on the Nov. 5 ballot.
An influential California newspaper recently urged against a November ballot measure, which would require certain healthcare providers in the state [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: New Filings in Missouri, Minnesota

Key motions were recently filed in state contract pharmacy litigation in Missouri and Minnesota.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

340B Health Leader Slams J&J Rebate Proposal, Urges Providers to ‘Remain Vigilant’ in Op-Ed

Maureen Testoni, the president and CEO of 340B Health celebrated J&J’s retreat from a 340B rebate proposal in an Oct. 9 RACmonitor op-ed.
The head of an influential 340B hospital advocacy group claimed “victory” in the recent fight against Johnson & Johnson’s (J&J) [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Providers Raise Caution on Claims Data Submission Requirements After 340B ESP Terms of Use Update Continues to Defer to Manufacturers

Second Sight Solutions updated 340B ESP's terms of use on Oct. 4.
Editor’s Note: An earlier version of this story incorrectly suggested that an Oct. 4 update to 340B ESP’s terms of [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Health Centers Urge Federal Appeals Court to Take Their Side in Case Alleging Drug Manufacturer Collusion on Contract Pharmacy Restrictions

Two community health centers argued in a Sept. 30 filing with the U.S. 2nd Circuit Court of Appeals that diabetes drugmakers colluded to place contract pharmacy restrictions.
Two community health centers urged a federal appeals court to overturn the dismissal of their 340B antitrust lawsuit, arguing in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

CMS Inaction on IRA-340B Conflicts May Drive ‘Manufacturer-Friendly’ Compliance Models

340B-IRA interactions
CMS has not assumed responsibility for “deduplicating” discounts that arise between the 340B program and the IRA's Medicare drug price negotiations.
Federal regulators’ inaction on the 340B program’s interactions with Medicare drug price negotiations will likely lead drugmakers to pursue “manufacturer-friendly” [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »

Head of Drug Industry-Funded Think Tank Backs J&J’s Proposed Rebate Model, Slams Hospitals in Op-Ed

Sally Pipes, the president and CEO of the drug-industry funded Pacific Research Institute, criticized pushback that led Johnson & Johnson to forgo its plans to implement a 340B rebate model in an Oct. 7 Forbes op-ed.
The leader of a right-leaning think tank that’s received funding from the drug industry criticized pushback that led Johnson & [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live